Sunshine Lake Pharma (HKG:6887) has launched an artificial intelligence-powered research and development platform focused on PROTAC (Protein Degradation-Targeting Chimeras) drug discovery, according to a Wednesday Hong Kong bourse filing.
Shares of the firm were down nearly 1% in Thursday morning trade.
The company said the platform integrates data analysis, computational modelling, and laboratory validation to support the design of PROTAC compounds.